Balcinrenone vs HRS-1780
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline
Balcinrenone
Developed by AstraZeneca
NCT04595370 · Phase 2 · completed
The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.
Next expected readout: July 2030 · NCT07624305 (registry estimate)
Reported efficacy
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) (missed)
Result source: NCT04595370
HRS-1780
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2030 · NCT07419828 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Balcinrenone | HRS-1780 |
|---|---|---|
| Kidney composite outcome | —Trial running · NCT07624305 | —Trial running · NCT07419828 |
| UACR, % change | -58.0% vs 230.3%−288.4 vs placeboNCT045953707 other results
| —Trial running · NCT07419828 |
| eGFR slope | —Trial running · NCT07624305 | —Trial running · NCT07419828 |
| Haemoglobin, change | —Trial running · NCT07624305 | —Trial running · NCT07419828 |
Kidney composite outcome
- Balcinrenone
- —Trial running · NCT07624305
- HRS-1780
- —Trial running · NCT07419828
UACR, % change
- Balcinrenone
- -58.0% vs 230.3%−288.4 vs placeboNCT04595370
7 other results
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -45.0% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -45.0% vs 230.3% NCT04595370
- HRS-1780
- —Trial running · NCT07419828
eGFR slope
- Balcinrenone
- —Trial running · NCT07624305
- HRS-1780
- —Trial running · NCT07419828
Haemoglobin, change
- Balcinrenone
- —Trial running · NCT07624305
- HRS-1780
- —Trial running · NCT07419828
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-1780: no structured comparison results are available for Chronic Kidney Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Balcinrenone: 4 of 4 rows · HRS-1780: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Balcinrenone |
|---|---|
| Dropout rate | 14.3%150 mga NCT04595370 · Phase 2 show 3 more results25%150 mg + 10 mg NCT04595370 · Phase 2 · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · combination |
| Discontinued due to AEs | 14.3%150 mga NCT04595370 · Phase 2 show 3 more results8.3%150 mg + 10 mg NCT04595370 · Phase 2 · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · combination |
| Serious AEs | 0%150 mga NCT04595370 · Phase 2 show 3 more results5.9%150 mg + 10 mg NCT04595370 · Phase 2 · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · combination |
| Most frequent reported AEs | 150 mga chronic kidney disease 16.7% (placebo 0%) gingival recession 16.7% (placebo 0%) headache 16.7% (placebo 0%) NCT04595370 · Phase 2 show 3 more results150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Balcinrenone
show 7 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Balcinrenone's landscape · HRS-1780's landscape